Switching From Terminal C5 to Proximal Complement Inhibitors in PNH: EVH Criteria, Transition Windows, and BTH Safeguards
PUBLISHED: 2026-11-19 · AUDITED: 2026-11-19 · ASH / IPIG EVIDENCE STANDARD
Patients on ravulizumab or eculizumab whose LDH is controlled below 1.5x ULN yet whose hemoglobin remains under 10.5 g/dL with high reticulocytes and a positive C3d Coombs test have C3-mediated extravascular hemolysis. Switching to oral iptacopan, subcutaneous pegcetacoplan, or adding oral danicopan raises hemoglobin by 2.4 to 3.6 g/dL while demanding strict adherence against breakthrough hemolysis.
1. Recognizing C3d-Mediated Extravascular Hemolysis (EVH) on C5 Therapy
When terminal C5 blockade works as designed, it stops the assembly of the C5b-9 membrane attack complex (MAC) on CD59-deficient red blood cells. Intravascular lysis halts, morning hemoglobinuria clears, and serum LDH drops to normal or near-normal levels (typically below 1.5x the upper limit of normal). However, PNH red blood cells also lack CD55 (Decay-Accelerating Factor), the surface regulator that keeps upstream C3 convertase in check. Under C5 monotherapy, surviving PNH erythrocytes accumulate dense C3b and C3d opsonin tags on their membranes. Macrophages in the spleen and liver recognize those C3 fragments and clear the tagged red blood cells prematurely, a process called C3-mediated extravascular hemolysis (EVH) (Brodsky, Blood 2021).
Before assuming that persistent anemia on ravulizumab or eculizumab is caused by EVH, hematologists must exclude four frequent mimics: underlying bone marrow failure (aplastic anemia or hypoplastic MDS), iron or folate deficiency, pharmacokinetic breakthrough hemolysis (where LDH climbs above 1.5x ULN right before the next infusion), and the rare C5 Arg885His polymorphism seen in roughly 3.2% of East Asian patients. Reviewing your longitudinal flow cytometry and hemolysis lab panel establishes whether EVH is truly driving your fatigue.
Clinically significant EVH leaves an unmistakable four-marker laboratory signature that separates it cleanly from bone marrow hypocellularity and intravascular relapse:
- Persistent Anemia Despite Controlled LDH: Hemoglobin stays below 10.5 g/dL (often 8.0 to 10.0 g/dL) or requires intermittent red cell transfusions while serum LDH stays below 1.5x ULN, proving that terminal C5 blockade is intact.
- Compensatory Reticulocytosis: Absolute reticulocyte count (ARC) remains persistently elevated above 100 to 120 x10^9/L (commonly 150 to 250 x10^9/L). If your reticulocytes are low (below 60 x10^9/L), the bone marrow itself is underproducing, pointing toward aplastic anemia or MDS overlap rather than isolated EVH.
- Positive Monospecific C3d Direct Antiglobulin Test (DAT / Coombs): A standard polyspecific Coombs test can miss weak opsonization, so ask specifically for monospecific anti-C3d and anti-IgG testing. Classic C5-associated EVH shows C3d positive / IgG negative erythrocytes.
- Mildly Elevated Indirect Bilirubin and Low Haptoglobin: Splenic macrophage digestion releases unconjugated bilirubin (often 1.5 to 3.5 mg/dL, occasionally causing mild scleral icterus) while haptoglobin remains depressed or undetectable.
Patients with this four-marker signature are prime candidates to discuss proximal complement inhibition with their hematologist. Leaving clinically symptomatic EVH untreated condemns patients to chronic hypoxic fatigue, elevated cardiac output strain, and ongoing iron overload if transfusions continue. Conversely, patients whose hemoglobin sits comfortably at 12.2 g/dL on eight-week intravenous ravulizumab (Study 301) with normal energy and zero transfusions rarely gain net clinical benefit from switching, especially if daily medication adherence is a personal concern (Lee et al., Blood 2019).
2. 24-Week Biomarker Trajectories: Oral Factor B vs. Subcutaneous C3 vs. Factor D Add-On
Three pivotal randomized Phase 3 trials directly enrolled patients with persistent anemia and extravascular hemolysis despite stable C5 therapy, allowing hematologists to compare expected laboratory recovery across all three proximal strategies: oral Factor B monotherapy with iptacopan (Peffault de Latour et al., NEJM 2024, APPLY-PNH), subcutaneous C3 inhibition with pegcetacoplan (Hillmen et al., NEJM 2021, PEGASUS), and dual terminal plus proximal blockade by adding oral Factor D inhibitor danicopan onto ongoing ravulizumab or eculizumab (Lee et al., The Lancet Haematology 2023, ALPHA).
Across all three trials, hematologic improvement follows a highly predictable kinetic timeline. Within the first 2 to 4 weeks after initiating proximal blockade, C3b opsonization on newly emerging PNH erythrocytes drops sharply. As splenic clearance ceases, hemoglobin climbs by 2.0 to 2.5 g/dL in the opening month, while the hyperactive bone marrow scales back erythropoiesis and absolute reticulocyte counts fall from roughly 195-238 x10^9/L down into the normal physiological range (78 to 108 x10^9/L) by Week 12. Meanwhile, Panel C illustrates the most reassuring safety metric for transitioning patients: serum LDH stays flat below 1.2x ULN across all three proximal regimens during steady state, confirming that intravascular hemolysis remains suppressed alongside extravascular rescue.
Notice two subtle distinctions between the three strategies when reading these trajectories. First, baseline hemoglobin differed slightly across trial entry criteria: ALPHA enrolled a more severely anemic cohort (mean baseline 7.7 g/dL, requiring hemoglobin <= 9.5 g/dL and reticulocytes >= 120 x10^9/L), which explains why danicopan plus C5 delivered a robust +2.9 g/dL absolute hemoglobin gain at Week 12 while landing at a mean of 10.6 to 10.8 g/dL. Second, in APPLY-PNH, 82.3% of iptacopan-treated patients achieved a hemoglobin increase of at least 2.0 g/dL without transfusions, and 68.8% reached an absolute hemoglobin of at least 12.0 g/dL (compared with 2.0% and 1.8% in the control arm continuing C5 monotherapy). In PEGASUS, pegcetacoplan outperformed eculizumab by an adjusted mean difference of +3.84 g/dL at Week 16 (with 85% transfusion avoidance vs. 15% on eculizumab) and normalized FACIT-Fatigue scores by +9.2 points.
3. Step-by-Step Switching Windows and Direct Proximal-to-Proximal Transitions
Timing the exact transition window between complement inhibitors is the single most critical operational step in preventing iatrogenic hemolytic flares. Because each agent reaches steady-state complement suppression on a different pharmacokinetic schedule, abrupt washout gaps can expose a large pool of surviving Type III PNH red cells to unopposed complement lysis. Equally important, real-world clinical experience now extends beyond C5-to-proximal switches to direct proximal-to-proximal transitions, such as a documented direct switch from oral iptacopan to subcutaneous pegcetacoplan without an intermediate C5 bridge (Latyshev et al., eJHaem 2026).
| Transition Pathway | Exact Timing & Overlap Window | Key Phase 3 / Clinical Evidence | Adherence & BTH Risk Profile | Best-Fit Patient Profile |
|---|---|---|---|---|
| Eculizumab / Ravulizumab to Iptacopan (Fabhalta) ORAL FACTOR B |
Start iptacopan 200 mg orally BID no later than 1 week after the last eculizumab dose, or no later than 6 weeks after the last ravulizumab dose. No prolonged C5 overlap required (rapid Factor B steady state within days). | APPLY-PNH (NEJM 2024): Mean Hb +3.59 g/dL; 68.8% Hb >= 12 g/dL; 94.8% transfusion-free at 24 weeks. | Half-life ~18-25h. Strict twice-daily compliance mandatory; missing multiple consecutive doses risks rapid rebound IVH. | Needle-averse adults with reliable pill routines who want complete EVH resolution and infusion-chair freedom. |
| Eculizumab / Ravulizumab to Pegcetacoplan (Empaveli) PROXIMAL C3 SC |
Administer pegcetacoplan 1,080 mg SC twice weekly concurrently with the patient's current C5 inhibitor for a mandatory 4-week run-in overlap, then discontinue the C5 inhibitor once steady-state C3 blockade is secured. | PEGASUS (NEJM 2021): +3.84 g/dL Hb advantage over eculizumab at Week 16; 85% transfusion avoidance; reticulocytes normalized. | Half-life ~8 days. More forgiving of a 24h delay than oral pills, but infection-driven pharmacodynamic BTH can be sharp; rescue SC/IV dosing protocols exist. | Patients preferring twice-weekly home SC pump or on-body injector with longer half-life buffer than daily oral capsules. |
| Add Danicopan (Voydeya) to Existing C5 Inhibitor FACTOR D ADD-ON |
Keep ongoing ravulizumab (q8w) or eculizumab (q2w) uninterrupted; add danicopan 150 mg orally TID (escalatable to 200 mg TID if Hb rise < 2 g/dL after 4 weeks). | ALPHA (Lancet Haematol 2023): +2.94 g/dL Hb gain at Week 12 vs. +0.50 g/dL on placebo + C5; 83% transfusion avoidance. | Built-in safety net: Even if oral danicopan doses are missed or GI illness impairs absorption, background C5 mAb prevents catastrophic intravascular BTH. | High-thrombosis-risk patients, frequent travelers, or anyone worried about oral missed-dose breakthrough crises. |
| Direct Switch: Iptacopan to Pegcetacoplan PROXIMAL-TO-PROXIMAL |
In patients experiencing intolerance or sub-optimal response on oral Factor B, initiate SC pegcetacoplan while overlapping iptacopan briefly until therapeutic pegcetacoplan levels stabilize, monitoring CBC, LDH, and bilirubin weekly (Latyshev et al., eJHaem 2026). | eJHaem 2026 Case Report: Demonstrated hematologic stability without severe breakthrough hemolysis or return to IV C5 bridging. | Requires close hematologist oversight, baseline C3/CH50/AH50 tracking where available, and pre-arranged rescue eculizumab availability. | Patients who cannot tolerate oral Factor B (e.g., dyslipidemia, GI side effects, or adherence barriers) yet still require proximal EVH control. |
Before initiating any proximal switch, confirm your encapsulated bacteria vaccination dossier. Unlike terminal C5 inhibitors, which primarily require quadrivalent Neisseria meningitidis (MenACWY) and serogroup B (MenB) immunization, proximal C3 and Factor B inhibitors (pegcetacoplan and iptacopan) block upstream opsonization and therefore require updated vaccination against three encapsulated organisms at least 2 weeks before the first dose: Neisseria meningitidis (MenACWY + MenB), Streptococcus pneumoniae (PCV20 or PCV21), and Haemophilus influenzae type b (Hib). If urgent switching cannot wait two weeks, prescribe prophylactic oral antibiotics (such as penicillin V or ciprofloxacin per REMS guidance) during the bridging window. Review complete vaccine schedules on our Living With PNH and Meningococcal Safety guide.
4. Breakthrough Hemolysis (BTH) Physics Under Proximal Blockade
Understanding breakthrough hemolysis under proximal inhibition requires recognizing a fascinating biological paradox explained in detail by Notaro and Luzzatto (NEJM 2022). On terminal C5 therapy alone, ongoing splenic EVH continuously trims down the population of PNH red blood cells, so your circulating PNH erythrocyte clone often sits around 45% to 65%. Once you switch to iptacopan or pegcetacoplan and shut off EVH, your CD55/CD59-deficient red blood cells survive a full 120-day lifespan. Within 3 to 6 months, your circulating PNH red blood cell clone routinely expands to 85% to 98%, matching your granulocyte clone size.
That dramatic red cell survival is the exact reason your hemoglobin jumps to 12.5 or 13.5 g/dL and your fatigue lifts. However, it also increases the total mass of complement-vulnerable erythrocytes circulating at any given moment. If a sudden complement-amplifying condition (CAC) strikes, such as influenza, COVID-19, bacterial gastroenteritis, major dental surgery, or trauma, or if a patient stops taking a short-half-life oral inhibitor abruptly, massive upstream complement activation can overwhelm C3 or Factor B blockade. Because almost every red blood cell in the bloodstream now lacks CD59, a proximal pharmacodynamic BTH episode can drive LDH steeply above 3x to 10x ULN and drop hemoglobin by 2 to 4 g/dL within 48 hours.
Fortunately, clinical trial extensions and real-world registries show that overall annual rates of clinical BTH remain low (roughly 3% to 10% per patient-year depending on trial definition and follow-up duration), and most episodes are manageable without switching back permanently if patients and clinicians act immediately:
- Rule 1: Never Skip Doses During Illness or Hospital Admission. Gastroenteritis with vomiting or NPO surgical fasting is the most dangerous moment for oral iptacopan users. Contact your hematology team immediately if you cannot keep two consecutive oral doses down so rescue IV or subcutaneous complement coverage can be arranged.
- Rule 2: Distinguish Dark Urine Plus Rising LDH From Minor Viral Aches. Keep a baseline copy of your normal LDH (for example, 185 U/L) on your phone. Any febrile illness accompanied by tea- or cola-colored urine, sudden back or abdominal pain, or LDH exceeding 2x ULN requires same-day lab verification and hematologist notification.
- Rule 3: Know the Rescue Escalation Playbook. For pegcetacoplan pharmacodynamic BTH, protocols permit intensified dosing (such as 1,080 mg every 3 days or temporary IV/SC escalation under specialist supervision). For severe BTH on any proximal monotherapy with hemodynamic instability or rapidly rising creatinine, a single rescue dose of a terminal C5 antibody (eculizumab) immediately caps C5b-9 intravascular lysis while the acute infection resolves. Keep our printable ER Physician Triage and Fever Card in your wallet at all times.
5. Six Questions to Bring to Your Hematologist Before Switching
Because PNH is ultra-rare, bringing a structured laboratory checklist turns a 15-minute follow-up appointment into an evidence-based shared decision:
1. Confirm True EVH Before Changing Drugs
Ask your hematologist to order a monospecific anti-C3d Coombs test, absolute reticulocyte count, indirect bilirubin, ferritin, transferrin saturation, and trough LDH drawn right before your next C5 infusion.
2. Audit Your Vaccine & Booster Dates
Verify exact completion dates for MenACWY, MenB, pneumococcal (PCV20/21), and Hib vaccines at least 14 days ahead of starting iptacopan or pegcetacoplan, and clarify whether your country recommends daily oral penicillin prophylaxis.
3. Match Drug Half-Life to Your Real-World Routine
Be completely honest about adherence: if twice-daily pills fit seamlessly into your morning and evening habits, oral iptacopan offers remarkable convenience. If travel, shift work, or memory barriers make missed doses likely, twice-weekly SC pegcetacoplan or dual C5 + danicopan add-on provides a stronger pharmacokinetic buffer.
4. Plan for Pregnancy or Upcoming Surgery First
If you plan to conceive within the next 12 to 24 months, discuss timing carefully: terminal C5 inhibition (especially eculizumab) currently carries the deepest maternal-fetal safety dataset, whereas oral small molecules generally require transitioning back to anti-C5 prior to pregnancy. See our Pregnancy and Perioperative PNH Dossier.
5. Write Down Your Specific BTH Rescue Plan
Before taking your first proximal dose, ask: If I develop a 38.5°C fever or dark urine on a Saturday night, which on-call hematology number do I call, and what exact rescue dose or antibiotic should the ER give?
6. Monitor Lipid Profile & Weekly Transition Labs
Check CBC, reticulocytes, LDH, and bilirubin at Weeks 2, 4, and 8 after switching to verify smooth hemoglobin ascent, and ask about periodic fasting lipid monitoring if starting oral iptacopan. Track ongoing trial updates in our Hematology Evidence Ledger.
Frequently Asked Questions from Patients & Families
Clear, compassionate answers grounded in ASH guidelines, IPIG consensus, and Phase 3 complement inhibitor clinical trials.
How do I know if my low hemoglobin on Ultomiris or Soliris is extravascular hemolysis (EVH)?
Clinically significant C3-mediated extravascular hemolysis is defined by four simultaneous findings on stable C5 therapy: hemoglobin below 10.5 g/dL (or transfusion dependence), controlled serum LDH below 1.5x the upper limit of normal, an elevated absolute reticulocyte count above 100 to 120 x10^9/L, and a positive monospecific C3d direct antiglobulin (Coombs) test. If reticulocytes are low, underlying bone marrow failure such as aplastic anemia should be investigated instead.
Primary sources: Brodsky, Blood 2021; PNH Flow Cytometry & Lab Decoder.
How do iptacopan (Fabhalta), pegcetacoplan (Empaveli), and danicopan (Voydeya) compare when switching from a C5 inhibitor?
All three proximal options resolve C3-mediated extravascular hemolysis and raise mean hemoglobin by roughly 2.4 to 3.6 g/dL while keeping LDH suppressed. Iptacopan is a twice-daily oral Factor B monotherapy capsule requiring strict daily adherence. Pegcetacoplan is a twice-weekly subcutaneous C3 infusion with an 8-day half-life and a mandatory 4-week overlap with your C5 drug during transition. Danicopan is a three-times-daily oral Factor D tablet added on top of ongoing ravulizumab or eculizumab, preserving a terminal C5 safety net against severe breakthrough hemolysis.
Phase 3 evidence: Peffault de Latour et al., NEJM 2024; Hillmen et al., NEJM 2021; Lee et al., Lancet Haematol 2023.
Is it safe to switch directly from one proximal inhibitor to another, such as from iptacopan to pegcetacoplan?
Yes, hematology teams can execute a direct proximal-to-proximal switch under close laboratory surveillance without necessarily bridging back to intravenous C5 therapy first. Published 2026 clinical evidence demonstrated a safe direct transition from oral iptacopan to subcutaneous pegcetacoplan with preserved hemoglobin stability and no severe breakthrough hemolysis, provided overlap timing covers the pharmacokinetic ramp-up and weekly LDH, hemoglobin, and bilirubin labs are tracked.
Clinical report: Latyshev et al., eJHaem 2026; Notaro & Luzzatto, NEJM 2022.